Search for "weapons of mass destruction" for cancer -- immuno/ gene therapy comes of age.
The complexity of a cancer, such as cell heterogeneity, and the existence of hypoxia, stromal cells and stem cells has so far prevented successful development and treatment of patients suffering from the later stages of cancers. At present, the use of conventional therapies, such as chemo/radio therapy is limited, and only therapies that are focused on utilizing the patient's immune response to combat against the disease appear to be the most reliable and promising. Two decades ago, cytokines were discovered to be able to activate the immune systems and mount an anti-tumour response. Then, dendritic cells were hailed as the most significant regulators of immunity and are employed in a variety of cancer management schemes. This review introduces current development in the field, focusing on combination of the components of the rapidly growing fields of immunotherapy and gene transfer/therapy, providing useful and significant detailed information for readers of cellular and molecular immunology.
Wei
Ming Q
MQ
Gene Therapy Unit, Department of Medicine, University of Queensland, Prince Charles Hospital, Brisbane, Australia. d.wei@mailbox.uq.edu.au
Metharom
Pat
P
Ellem
Kay A O
KA
Barth
Stefan
S
D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000970:Antineoplastic Agents